SPN-817

SPN-817 · Supernus Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for SPN-817, covering 2025-02-06 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy [Phase 2]